POMDOCTOR LIMITED Faces Potential Delisting from Nasdaq Amid Stock Price Concerns

POMDOCTOR LIMITED, a company listed on Nasdaq with the ticker POM, is navigating challenging waters following the receipt of a determination letter from the Nasdaq Listing Qualifications Department. This correspondence, dated October 6, 2026, indicates that the company's stock has not met the minimum bid price requirement of $1.00 per share, a threshold that the company failed to maintain for 30 consecutive business days from August 24 to October 5, 2026.

What Led to This Situation?

The struggle began when POMDOCTOR experienced a significant dip in its American depositary shares (ADSs), causing them to fall below the crucial $1.00 mark. Under normal circumstances, companies receive a 180-day grace period to rectify such a situation. However, POMDOCTOR's recent activity complicates matters; the company had performed a 1-for-18 reverse stock split on June 22, 2026. This action effectively nullified its eligibility for any compliance grace period, as per Nasdaq Listing Rule 5810(c)(3)(A)(iv).

As a consequence, Nasdaq notified the company of the impending delisting of its securities from the Nasdaq Global Market. If POMDOCTOR does not file a timely appeal, its shares will be suspended from trading beginning on October 15, 2026. The aftermath would result in a Form 25-NSE being filed with the U.S. Securities and Exchange Commission, which would finalize the removal of its securities from Nasdaq listing and registration.

What Are POMDOCTOR's Next Steps?

In light of this challenging situation, POMDOCTOR aims to appeal Nasdaq's determination to a Hearings Panel. The company has until October 13, 2026, to lodge this appeal. A timely request for a hearing will delay the suspension and any subsequent delisting action until a decision is made by the Panel.

POMDOCTOR's management has signalled its intent to present a robust plan aimed at regaining compliance with Nasdaq's continuing listing standards during this hearing. Nevertheless, there is no guarantee that the Panel will grant the company additional time or that the plan will be successful. The health of POMDOCTOR's stock will heavily influence the decision-making process of the Panel.

Broader Implications for POMDOCTOR

POMDOCTOR LIMITED operates in the digital healthcare sector, targeting advancements in AI-enabled healthcare solutions and predictive health capabilities. The stakes are particularly high given that a delisting from Nasdaq could severely affect investor confidence and the company’s market perception. POMDOCTOR's future hinges not only on its compliance with listing requirements but also on broader market conditions and its operational performance in an increasingly competitive healthcare landscape.

With no assurance of success in their appeal, POMDOCTOR is also exploring various strategies to enhance its stock price and shareholder value. These strategies may include leveraging artificial intelligence technologies more effectively, optimizing existing healthcare payment networks, and utilizing real-world healthcare data to provide targeted healthcare services.

Conclusion

As POMDOCTOR navigates this tumultuous period, stakeholders within the digital healthcare community are watching closely. This situation emphasizes the importance of maintaining compliance with listing standards on major stock exchanges and the significant impact that stock performance has on the operational capabilities of companies in the rapidly evolving healthcare sector. The next few days will be crucial for POMDOCTOR as it prepares its appeal and looks for ways to boost its stock price to remain listed and operational within the Nasdaq framework.